On March 5, 2024 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), reported that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and EED inhibitor APG-5918, have been selected for presentations at the 2024 American Association of Cancer Research Annual Meeting (AACR 2024) (Press release, Ascentage Pharma, MAR 5, 2024, View Source;ascentage-pharma-to-present-three-preclinical-studies-at-2024-american-association-of-cancer-research-annual-meeting-302080735.html [SID1234640814]). These abstracts are now available on the AACR (Free AACR Whitepaper)’s official website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) annual meeting is one of the world’s largest and longest-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community. This year’s AACR (Free AACR Whitepaper) annual meeting will be held from April 5-10 2024, in San Diego, California, USA.
These three preclinical abstracts from Ascentage Pharma include:
Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms
Abstract#: 1971
Session Category: Experimental and Molecular Therapeutics
Session Title: Kinase and Phosphatase Inhibitors 2
Session Time: Monday April 8, 2024, 9:00 AM – 12:30 PM, Pacific Time
Results from this preclinical study show that in SDH-deficient cancer cells, olverembatinib has superior efficacy compared to other approved tyrosine kinase inhibitors. Mechanistically, olverembatinib can exert its antitumor effects in SDH-deficient neoplasms by modulating multiple signal pathways involved in cell hypoxia, angiogenesis, proliferation, and survival. These results provide a scientific rationale for the future development of olverembatinib in SHD-deficient cancers with an urgent unmet medical need.
Embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and MDM2 inhibitor alrizomadlin (APG-115) synergistically inhibit tumor growth in preclinical models of prostate cancer (PCa)
Abstract#: 3223
Session Category: Experimental and Molecular Therapeutics
Session Title: Epigenetic Targets
Session Time: Monday April 8, 2024, 1:30 PM – 5:00 PM, Pacific Time
Results from this preclinical study show that in preclinical models of PCa, targeting both EED and MDM2 can synergistically enhance antitumor activities by modulating pathways related to DNA methylation, cell cycle, and apoptosis. These findings provide a scientific rationale for the future clinical development of APG-5918 in combination with alrizomadlin for the treatment of PCa.
APG-2449, a novel focal adhesion kinase (FAK) inhibitor, inhibits metastasis and enhances the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in epithelial ovarian cancer (EOC)
Abstract#: 4569
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Combinations
Session Time: Tuesday April 9, 2024, 9:00 AM – 12:30 PM, Pacific Time
Results from this preclinical study show that the novel FAK inhibitor APG-2449 can reduce the metastasis of tumor cells and achieve synergistic antitumor effects with PLD in xenograft mouse models of ovarian cancer. These results support the future clinical development of APG-2449 in combination with PLD for the treatment of ovarian cancer.